eTable 2.
Hazard Ratio (95% Confidence Interval) | ||||
---|---|---|---|---|
|
||||
Men | Women | |||
|
|
|||
Dementia Status | Model 1a | Model 2b | Model 1a | Model 2b |
| ||||
Total Dementia (n=2547 [1503 Women, 1044 Men]) | ||||
Diabetes only | 1.52 (0.95–2.42) | 1.43 (0.89–2.30) | 1.34 (0.84–2.16) | 1.43 (0.88–2.32) |
APOE ε4 only | 1.55 (1.06–2.26) | 1.59 (1.08–2.34) | 2.47 (1.86–3.26) | 2.47 (1.86–3.29) |
Bothc | 3.05 (1.62–5.75) | 2.38 (1.24–4.54) | 3.88 (1.87–8.05) | 4.72 (2.23–10.0) |
| ||||
AD (n=2343 [1394 Women, 949 Men]) d | ||||
Diabetes only | 1.85 (0.88–3.91) | 1.87 (0.88–4.00) | 1.31 (0.67–2.55) | 1.53 (0.77–3.04) |
APOE ε4 only | 2.32 (1.33–4.04) | 2.57 (1.44–4.56) | 2.82 (1.95–4.09) | 2.78 (1.91–4.04) |
Bothe | 4.90 (2.13–11.27) | 4.78 (2.02–11.30) | 4.94 (1.95–12.49) | 5.95 (2.29–15.5) |
| ||||
Mixed AD (n=2268 [1332 Women, 936 Men]) d | ||||
Diabetes only | 1.53 (0.70–3.34) | 1.37 (0.62–3.06) | 2.10 (0.96–4.56) | 2.06 (0.91–4.68) |
APOE ε4 only | 1.30 (0.65–2.59) | 1.25 (0.63–2.52) | 3.56 (2.14–5.95) | 3.55 (2.10–5.99) |
Bothc | 3.52 (1.06–11.72) | 2.19 (0.62–7.64) | 7.80 (2.30–26.42) | 10.37 (2.94–35.53) |
| ||||
VaD (n=2194 [1283 Women, 911 Men]) f | ||||
Diabetes only | 0.89 (0.26–3.00) | 0.80 (0.23–2.75) | 1.02 (0.23–4.42) | 0.93 (0.20–4.42) |
APOE ε4 only | 1.06 (0.42–2.65) | 1.04 (0.41–2.63) | 0.80 (0.27–2.35) | 0.79 (0.25–2.37) |
Bothe | 1.28 (0.17–9.71) | 0.55 (0.07–4.45) | NE | NE |
Abbreviations: AD, Alzheimer disease; APOE ε4, ε4 allele of the apolipoprotein E genotype; NE, not estimable due to small sample size; VaD, vascular dementia.
Adjusted for age and years of education.
Adjusted for age, years of education, hypertension, total cholesterol, smoking, alcohol, race, body mass index, depression status, ankle-brachial index, and stroke.
Cross-product between diabetes/APOE ε4 subgroups and sex, P>.1. The analysis was adjusted as in model 1.
Excluded participants with VaD and other types of dementia.
Cross-product between diabetes/APOE ε4 subgroups and sex, P>.2. The analysis was adjusted as in model 1.
Excluded participants with AD and other types of dementia.